Pharmaceutical - Enbrel

Filter

Current filters:

Enbrel

Popular Filters

Mixed Ph III data for Pfizer’s tofacitinib vs Enbrel in plaque psoriasis

24-03-2014

US pharma giant Pfizer has announced detailed results from OPT Compare (A3921080), a Phase III study…

DermatologicalsEnbrelPfizerPharmaceuticalResearchtofacitinibXeljanz

Pfizer revenues down as patent losses hit sales

Pfizer revenues down as patent losses hit sales

29-10-2013

Global pharma giant Pfizer has said worldwide sales fell 2% to $12.6 billion, hurt by generic competition,…

AriceptEliquisEnbrelFinancialLipitorNorth AmericaPfizerPharmaceuticalRebifSpiriva

Generics triple-therapy just as effective as brand-name Enbrel, new study shows

13-06-2013

Global biotech leader Amgen's (Nasdaq: AMGN) branded drug Enbrel (etanercept) is no more effective in…

AmgenAnti-Arthritics/RheumaticsEnbrelGenericsmethotrexatePharmaceuticalResearch

Steady sales for MAbs in rheumatoid arthritis - can biologics beat the patent cliff?

13-02-2013

Since 2004, the market for monoclonal antibodies (MAbs) in rheumatoid arthritis (RA) has experienced…

Anti-Arthritics/RheumaticsBiotechnologyEnbrelHumiraMarkets & MarketingPharmaceuticalRemicade

Takeda loses distribution of 13 Pfizer products in Japan

19-06-2012

Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502) has concluded an agreement that, as of December…

Asia-PacificBenefixEnbrelLicensingMarkets & MarketingPfizerPharmaceuticalPrevenarTakeda Pharmaceuticals

Amgen’s gets new US patent for Enbrel, giving protection until 2028

24-11-2011

Global biotech leader Amgen (Nasdaq: AMN) has announced the issuance of a new patent, US Patent No 8,063,182,…

AmgenAnti-Arthritics/RheumaticsBiotechnologyEnbrelNorth AmericaPatentsPharmaceuticalRoche

Study identifies factors linked with better medication response for treatment of juvenile arthritis

07-11-2011

Among patients with juvenile idiopathic arthritis (JIA) who initiated treatment with the drug etanercept…

AmgenAnti-Arthritics/RheumaticsEnbreletanerceptPfizerPharmaceuticalResearch

Back to top